1. sayfa ve
Tekrarlanan kayıtlar tek bir kaynakta birleştirilmektedir.
1
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19-associated encephalopathy: Neurological manifestation of COVID-19 Coronavirus disease 2019 (
COVID-
19) is a viral disease, also known as severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China COVID-
19-associated neurological manifestations have not been widely reported. In this report, we describe a case of encephalopathy in a patient with
COVID-
19 infection. Covid-19
2
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19 solution Some CoVs have recently entered humans from infected animals and lastly we have SARS
COVID-
19, (CoV), which causes severe acute, often fatal respiratory sars covid-19
3
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Why COVID-19? Covid-
19 has been estimated to have a case fatality rate of around 3%. In late December 2019, an outbreak of
COVID-
19 was reported from Wuhan city, China. Today
COVID-
19 has affected more than 212 countries and has made billions of people to be quarantined in their houses.
4
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Fighting COVID-19 Abstract The current
COVID-
19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and covid-19
5
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Asymptomatic COVID-19 Infection Management: The Key to Stop COVID-19 The
COVID-
19 disease, emerged in December 2019, has spread rapidly, with new cases confirmed in multiple countries. portion of the population to virus and increase the late diagnosis and thereafter enhance
COVID-
19 mortality. Thereafter, it is fundamental to review our
COVID-
19 screening approach and enlarge
COVID-
19 testing to the general population by using rapid testing appliances COVID-19
6
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19: Immunopathogenesis Coronavirus-
19 disease (
COVID-
19) first described in Wuhan, China at the end of 2019. respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks may help to elucidate the pathogenesis of
COVID -
19.
7
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID 19: Neuromuscular manifestations COVID-
19 pandemic is ongoing and information on the neurological aspects of this viral infection is being gathered. This manuscript studies the available information on the neuromuscular manifestations of
COVID-
19. covid-19 neurological manifestations covid-19 neuromuscular manifestations
8
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Tobacco and COVID-19 Similar data have been approved found for coronavirus disease-2019 (
COVID-
19) pandemic. adverse effects of tobacco and tobacco products and to raise awareness among the public and to make efforts to smoking on every opportunity during the
COVID -
19 pandemic. covid-19
9
Dergi Makalesi

Dergi Makalesi

Kaynak
1:
Kaynak
2:
Yazar(lar) :
Yıl :
2020
Pathogenesis of COVID-19 The coronavirus disease 2019 (
COVID-
19) is a very contagious infectious disease which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV The aim of this report is to review the immunopathogenesis of
COVID-
19 in the light of current literature. covid-19
10
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China Background: Faced with the coronavirus disease 2019 (
COVID-
19) pandemic, the development of
COVID-
19 vaccines has been progressing at an unprecedented of vaccines against
COVID-
19 during the pandemic. -
19 vaccination or valuing doctor’s recommendations could increase the probability of accepting
COVID-
19 vaccination as soon as possible, while having COVID-19
11
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19: immunopathogenesis and Immunotherapeutics Abstract The recent novel coronavirus disease (
COVID-
19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a Therefore, mechanisms underlying immune abnormalities in patients with
COVID-
19 must be elucidated to guide clinical management of the disease. strategies against
COVID-
19.
12
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19 and our DNA covid-19
13
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
ACE2, Metformin, and COVID-19 Summary:
COVID-
19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available. Angiotensin converting enzyme 2 (ACE2) is essential to
COVID-
19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of
COVID-
19.
14
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
SARS-CoV-2(COVID-19) viruses to more severe diseases such as Severe Acute Respiratory Syndrome (SARS) during 2002, Middle East Respiratory Syndrome (MERS) during 2012, and the
COVID -
19 that started during December 2019 in Wuhan, China.
15
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19: an updated review COVID-
19 is a zoonotic disease that showed higher levels of transmissibility in humans. So, all the world scientists today are in a race against time to find a vaccine or treatment to
COVID-
19, which requires a deeper understanding. covid-19
16
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
From SARS to COVID-19: What we have learned about children infected with COVID-19 There has been extensive research performed on SARS; however, the understanding of the pathophysiological impact of coronavirus disease 2019 (
COVID-
19) -
19. Newborns, asymptomatic children and normal chest imaging cases emerged in
COVID-
19 literature. COVID-19
17
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Novel Coronavirus Infection: COVID-19 The most recent coronavirus, SARS-CoV-2, causing
COVID-
19 disease was identified in 2019. There is no specific antiviral drug for
COVID-
19 infection. The main protection measure is to avoid contact with the person infected with
COVID-
19. covid-19
18
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
COVID-19 and Neurological Manifestations Coronavirus disease 2019 (
COVID-
19) is a viral illness caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) which has taken the form We therefore reviewed the neurological diseases or complications associated with COIVID-
19 in available literature. covid-19
19
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
Current strategies against COVID-19 Abstract Coronavirus disease (
COVID-
19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently was declared a pandemic by world This review will be not only helpful for the current situation of
COVID-
19, but can also play a major role in such epidemics in the future. COVID-19
20
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19: Knowns, Unknowns, and Questions covid-19
21
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Bolevich Sergey Brankovich
,
Litvitsky Peter Frantzevich
,
Grachev Sergei Vitalievich
,
Vorobyev Sergey Ivanovich
,
Orlova Alexandra Sergeevna
,
Fokina Marina Anatolievna
,
Novikov Alexei Alekseevich
,
Bolevich Stephani Sergeevna
,
Mikhaleva Anastasia Yurievna
,
Morozova Elena Mihailovna
,
Kartashova Maria Konstantinovna
,
Yavlieva Koka Hasbulatovna
,
Gudanovich Denis Vitalievich
,
Srejovic Ivan
,
Jakovljevic Vladimir
Yıl :
2020
Fundamental Basis of COVID-19 Pathogenesis On February 11th, 2020, the World Health Organization assigned the official name of the infection caused by the new coronavirus –
COVID-
19. COVID-
19 has affected people from all over the world given that the infection was noted in 200 countries resulting in annunciation of the pandemic situation The initial stage of
COVID-
19 infection is the penetration of SARS-CoV-2 into target cells that have angiotensin converting enzyme type II receptors. coronavirus – covid-19
22
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19: etiology, clinical picture, treatment virus, its current taxonomy, ecology, virion morphology, life cycle, molecular biology, pathogenesis and clinical picture of the etiologically related
COVID -
19 (Coronavirus disease 2019) as well as data available in the scientific literature on the anti-SARS-CoV-2-effectiveness of passive immunotherapy and most debated drugs used to treat
COVID-
19: Chloroquine, Hydroxychloroquine, Nitazoxanide, Ivermectin, Lopinavir and Ritonavir, Camostat mesilate, Remdesivir covid-19
23
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
The hallmarks of COVID-19 disease. The clinical features of
COVID-
19, such as fever, cough, shortness of breath, and fatigue, are similar to those of many acute respiratory infections. There is currently no specific treatment for
COVID-
19, but antiviral therapy combined with supportive care is the main strategy. Here, we summarize recent progress in understanding the epidemiological, virological, and clinical characteristics of
COVID-
19 and discuss potential targets
24
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Meng Xu
,
Dan Wang
,
Hongye Wang
,
Xiaomei Zhang
,
Te Liang
,
Jiayu Dai
,
Meng Li
,
Jiahui Zhang
,
Kai Zhang
,
Danke Xu
,
Xiaobo Yu
Yıl :
2020
COVID‐19 diagnostic testing: Technology perspective Abstract The corona virus disease 2019 (
COVID‐
19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since
COVID‐
19 can Here, we provide a comprehensive review of the different primary technologies used to test for
COVID‐
19 infection, discuss the advantages and disadvantages COVID‐19
25
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Current Avenues for COVID-19 Serology Development of rapid, reliable, and easy diagnostic tests with high-throughput is the need of the hour for laboratories combating the
COVID-
19 pandemic Timely diagnosis, effective treatment, and future prevention are key to management of
COVID-
19. covid-19 serological tests
26
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Cléa Melenotte
,
Aymeric Silvin
,
Anne-Gaëlle Goubet
,
Imran Lahmar
,
Agathe Dubuisson
,
Alimuddin Zumla
,
Didier Raoult
,
Mansouria Merad
,
Bertrand Gachot
,
Clémence Hénon
,
Eric Solary
,
Michaela Fontenay
,
Fabrice André
,
Markus Maeurer
,
Giuseppe Ippolito
,
Mauro Piacentini
,
Fu-Sheng Wang
,
Florent Ginhoux
,
Aurélien Marabelle
,
Guido Kroemer
,
Lisa Derosa
,
Laurence Zitvogel
Yıl :
2020
Immune responses during COVID-19 infection The unpredictability of coronavirus disease-
19 (
COVID-
19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe
COVID-
19, insufficient diagnostic tools for the detection of SARS-CoV covid-19
27
Dergi Makalesi

Dergi Makalesi

Yazar(lar) :
Yıl :
2020
Macrophage activation syndrome and COVID-19 Severe
COVID-
19 is often associated with hypercytokinemia, which is typically found in macrophage activation syndrome. Although we have not fully understood the physiological and pathological aspects of
COVID-
19, current research progress indicates the effectiveness of Here, we summarize macrophage activation syndrome and its possible contribution to
COVID-
19, and cytokine targeted attempts in severe
COVID-
19 cases. COVID-19
28
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2020
COVID-19 Therapeutic Options Under Investigation Since its emergence in China in December 2019,
COVID-
19 has quickly spread around the globe causing a pandemic. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce
COVID-
19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of
COVID-
19 patients. COVID-19
29
Dergi Makalesi

Dergi Makalesi

Kaynak
:
Yayıncı:
Springer Nature
Konu :
Biomedicine, general, Biomedical Engineering/Biotechnology
Yıl :
2020
COVID-19 remedies Repurposed drugs, inhibitors of inflammatory cytokines, neutralizing monoclonal antibodies and sera from convalescent patients will help ease the burden of
COVID -
19 on healthcare systems.